LC method for therapeutic drug monitoring of levetiracetam: Evaluation of the assay performance and validation of its application in the routine area

Clinical Biochemistry

Volumn 43, Issue 4-5, 2010, Pages 473-482

  Zufía, Laura ^a   Aldaz, Azucena ^a   Ibáñez, Nerea ^a   Giráldez, Joaquín ^a   Viteri, César ^b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Instituto de Investigación Sanitaria de Navarra   (Spain)

Author keywords

Accuracy profile; HPLC; Levetiracetam; Therapeutic Drug monitoring; Validation

Indexed keywords

ETIRACETAM;

ACCURACY; ANALYTIC METHOD; ARTICLE; CALIBRATION; CONTROLLED STUDY; DIODE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; EVALUATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERNAL BIAS; PERFORMANCE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; QUALITY CONTROL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; HUMANS; LIMIT OF DETECTION; LINEAR MODELS; PIRACETAM; QUALITY CONTROL; RISK FACTORS; VALIDATION STUDIES AS TOPIC;

EID: 76749108393     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.10.014     Document Type: Article

References (36)

1. Shorvon S. Pyrrolidone derivatives. Lancet 358 (2001) 1885-1892
2. Hovinga C.A. Levetiracetam: a novel antiepileptic drug. Pharmacotherapy 21 (2001) 1375-1388
3. Cereghino J., Biton V., Abou-khalil B., Dreifuss F., Gauer L., and Leppik I. Levetiracetam for partial seizures. Neurology 55 (2000) 236-242
4. Schachter S.C. The next wave of anticonvulsants: focus on levetiracetam, oxcarbazepine and zonisamide. CNS Drugs 14 3 (2000) 229-249
5. Patsalos P. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol. Ther. 85 (2000) 77-85
6. Strolin Benedetti M., Whomsley R., and Nicolas J.M. Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur. J. Clin. Pharmacol. 59 (2003) 621-630
7. Perucca E., and Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin. Pharmacokinet. 31 (1996) 29-46
8. Pellock J.M., Glauser T.A., Bebin E.M., Fountain N.B., Ritter F.B., Coupez R., et al. Pharmacokinetic study of levetiracetam in children. Epilepsia 42 (2001) 1574-1579
9. Vermeij T.A.C., and Edelbroek P.M. High-performance liquid chromatographic and megabore gas-liquid chromatographic determination of levetiracetam (ucb L059) in human serum after solid-phase extraction. J. Chromatogr., B 662 (1994) 134-139
10. Isoherranen N., Roeder M., Soback S., Yagen B., Schuring V., and Bailer M. Enantioselective analysis of levetiracetam and its enantiomer R-α-ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion trap mass spectrometric detection. J. Chromatogr., B 745 (2000) 325-332
11. Ratnaraj N., Doheny H.C., and Patsalos P.N. A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb L059) in serum or plasma by high performance liquid chromatography. Ther. Drug Monit. 18 (1996) 154-157
12. Grim S.A., Ryan M., and Miles M.V. Correlation of levetiracetam concentrations between serum and saliva. Ther. Drug Monit. 25 (2003) 61-66
13. Pucci V., Bugamelli F., Mandrioli R., Ferranti A., Kenndler E., and Raggi M.A. High performance liquid chromatographic determination of levetiracetam in human plasma: comparison of different sample clean-up procedures. Biomed. Chromatogr. 18 (2004) 37-44
14. Rao B.M., Ravi R., Shyam Sundar Reddy B., Sivakumar S., Gopi Chand I., Praveen Kumar K., et al. method for the enantioselective analysis of Levetiracetam and its enantiomer R-α-ethyl-2-oxo-pyrrolidine acetamide on amylose-based stationary phase. J. Pharm. Biomed. Anal. 35 (2004) 1017-1026
15. Martens-Lobenhoffer J., and Bode-Boger S.M. Determination of levetiracetam in human plasma with minimal sample pretreatment. J. Chromatogr., B 819 (2005) 197-200
16. Juenke J.M., Brown P.I., Urry F.M., and McMillin G.A. Drug monitoring and toxicology: a procedure for the monitoring of levetiracetam and zonisamide by HPLC-UV. J. Anal. Toxicol. 30 (2006) 27-30
17. Lancelin F., Franchon E., Kraoul L., Garciau I., Brovedani S., Tabaouti K., et al. Therapeutic drug monitoring of levetiracetam by High-performance liquid chromatography with photodiode array ultraviolet detection: preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epilepsy. Ther. Drug Monit. 29 (2007) 576-583
18. Contin M., Mohamed S., Albani F., Riva R., and Baruzzi A. Simple and validated HPLC-UV analysis of levetiracetam in deproteinized plasma of patients with epilepsy. J. Chromatogr., B 873 (2008) 129-132
19. Jain D., Subbaiah G., Sanyal M., Pal U., and Shrivastav P. Determination of levetiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to bioequivalence studies. Rapid Commun. Mass Spectrom. 20 (2006) 2539-2547
20. Guo T., Oswald L.M., Mendu D.R., and Soldin S.J. Determination of levetiracetam in human plasma/serum/saliva by liquid chromatography-electrospray tandem mass spectrometry. Clin. Chim. Acta 375 (2007) 115-118
21. Matar K.M. Quantification of levetiracetam in human plasma by liquid chromatography-tandem mass spectrometry: Application to therapeutic drug monitoring. J. Pharm. Biomed. Anal. 48 (2008) 822-828
22. May T.W., Rambeck B., and Jürgens U. Serum concentrations of levetiracetam in epileptic patients the influence of dose and co-medication. Ther. Drug Monit. 25 (2003) 690-699
23. Boulanger B., Chiap P., Dewé W., Crommen J., and Hubert P.h. An analysis of the SFSTP guide on validation of chromatographic bioanalytical methods: progresses and limitations. J Pharm Biomed Anal 32 (2003) 753-765
24. Hubert P.h., Nguyen-Huu J.J., Boulanger B., Chapuzet E., Chiap P., Cohen N., et al. Validation of quantitative analytical procedures, harmonization of approaches. STP Pharma Pratiques 13 3 (2003) 101-138
25. Hubert P.h., Nguyen-Huu J.J., Boulanger B., Chapuzet E., Chiap P., Cohen N., et al. Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal: Part I. J. Pharm. Biomed. Anal. 36 (2004) 579-586
26. Hubert P.h., Nguyen-Huu J.J., Boulanger B., Chapuzet E., Chiap P., Cohen N., et al. Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal: Part II. J. Pharm. Biomed. Anal. 45 (2007) 70-81
27. Hubert P.h., Nguyen-Huu J.J., Boulanger B., Chapuzet E., Cohen N., Compagnon P.A., et al. Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal: Part III. J. Pharm. Biomed. Anal. 45 (2007) 82-93
28. Hubert P.h., Nguyen-Huu J.J., Boulanger B., Chapuzet E., Cohen N., Compagnon P.A., et al. Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal: Part IV. Examples of application. J. Pharm. Biomed. Anal. 48 (2008) 760-771
29. Zufía L., Aldaz A., Ibáñez N., and Viteri S. LC method for the therapeutic drug monitoring of lamotrigine: evaluation of the assay performance and validation of its application in the routine area. J. Pharm. Biomed. Anal. 49 (2009) 547-553
30. Gonzalez G., and Herrador M.A. Accuracy profiles from uncertainty measurements. Talanta 70 (2006) 896-901
31. Guidance for industry: Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), May 2001.
32. Shah V.P., Midha K.K., Dighe S., MacGilveray I.J., Skelly J.P., Yacobi A., et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. J. Pharm. Sci. 81 (1992) 309-312
33. Shah V.P., Midha K.K., Findlay J.W.A., Hill H.M., Hulse J.D., MacGilveray I.J., et al. Bioanalytical method validation: a revisit with a decade of progress. Pharm. Res. 17 (2000) 1551-1557
34. ISO5725-1, Application of the statistics-accuracy (trueness and precision) of the results and methods of measurement: Part 1, General principles and definitions, International Organization for Standardisation (ISO), Geneva, Switzerland.
35. Shah V.P., Midha K.K., Dighe S., McGilveray I.J., Skelly J.P., Yacobi A., et al. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. Pharm. Res. 9 4 (1992) 588-592
36. Mee R. Estimation of the percentage of a normal distribution lying outside a specified interval. Commun. Stat., Theory Methods 17 5 (1988) 1465-1479